Clonotype Profiling for Lymphoid Neoplasm Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring autoimmune diseases and lymphoid cancers lack the sensitivity and specificity to detect and track specific T and B cells involved in disease processes, particularly those that have undergone modifications or are present at low levels.
Innovation Solution
The development of sequence-based profiles of immune repertoires, or clonotype profiles, using next-generation sequencing technologies to identify patient-specific clonotypes correlated with diseases, allowing for monitoring of disease conditions without the need for patient-specific reagents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard immunological techniques are used to detect circulating autoantibodies, then the diagnosis of autoimmune diseases can be performed, but the sensitivity and specificity to detect specific T and B cells involved in disease processes is insufficient
Solution Approach 1:
The patent replaces traditional mechanical/chemical immunological detection methods with molecular sequencing techniques. Specifically, it uses next-generation sequencing to analyze T-cell receptor (TCR) and B-cell receptor (BCR) gene sequences, enabling detection of specific clonotypes at the molecular level rather than relying on bulk antibody detection methods.
Solution Approach 2:
The patent segments the immune repertoire analysis by focusing on specific gene regions (TCR alpha/beta chains, BCR heavy/light chains) and identifying individual clonotypes within the diverse immune population. This segmentation allows precise detection of disease-associated specific T and B cells rather than measuring overall immune activity.
2Measurement precision
If clonal expansion is detected using spectratyping, then evidence of clonal expansion can be obtained, but many distinct sequences with the same length remain indistinguishable
Solution Approach 1:
The patent replaces spectratyping's size-based separation mechanism with direct DNA sequencing. This substitution eliminates the limitation of size equivalence by reading the actual nucleotide sequences, allowing distinction between any two clonotypes regardless of their amplicon lengths or similarities.
Solution Approach 2:
The patent transitions from one-dimensional size measurement (spectratyping) to multi-dimensional sequence analysis. By sequencing the actual nucleotide compositions and comparing them against reference databases, the system achieves precise identification of clonotypes based on their molecular sequence signatures rather than solely on fragment size.
3Measurement precision
If patient-specific reagents are used for monitoring, then specific disease-correlated clonotypes can be detected, but the complexity and cost of developing patient-specific assays increases
Solution Approach 1:
The patent develops a universal monitoring platform based on next-generation sequencing that can detect any clonotype without requiring patient-specific reagents. The system uses standardized sequencing protocols and computational algorithms that work across different patients and disease states, eliminating the need to develop custom assays for each patient while maintaining high specificity.
Solution Approach 2:
Instead of creating patient-specific physical reagents, the patent uses digital copies of reference clonotype sequences stored in databases. The system compares sequenced samples against these digital references to identify disease-associated clonotypes, replacing the need for physical patient-specific antibodies or probes with computational pattern recognition.
Data Source
AI summary
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.